The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1−/−myopathic mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and purpose: We have investigated the therapeutic effects of the selective cyclophilin inhibitor D‐MeAla 3‐EtVal 4‐cyclosporin (Debio 025) in myopathic Col6a1−/−mice, a model of muscular dystrophies due to defects of collagen VI. Experimental approach: We studied calcineurin activity based on NFAT translocation; T cell activation based on expression of CD69 and CD25; propensity to open the permeability transition pore in mitochondria and skeletal muscle fibres based on the ability to retain Ca 2+and on membrane potential, respectively; muscle ultrastructure by electronmicroscopy; and apoptotic rates by terminal deoxynucleotidyl transferase‐mediated dUTP nick end labelling assays in Col6a1−/−mice before after treatment with Debio 025. Key results: Debio 025 did not inhibit calcineurin activity, yet it desensitizes the mitochondrial permeability transition pore in vivo. Treatment with Debio 025 prevented the mitochondrial dysfunction and normalized the apoptotic rates and ultrastructural lesions of myopathic Col6a1−/−mice. Conclusions and implications: Desensitization of the mitochondrial permeability transition pore can be achieved by selective inhibition of matrix cyclophilin D without inhibition of calcineurin, resulting in an effective therapy of Col6a1−/−myopathic mice. These findings provide an important proof of principle that collagen VI muscular dystrophies can be treated with Debio 025. They represent an essential step towards an effective therapy for Ullrich Congenital Muscular Dystrophy and Bethlem Myopathy, because Debio 025 does not expose patients to the potentially harmful effects of immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 2×
“After binding to its inhibitory ligand CsA (Borel et al., 1977), the CsA/CyPA complex binds to and inhibits the cytosolic phosphatase calcineurin (Liu et al., 1991) resulting in immunosuppression (Clipstone and Crabtree, 1992; Walsh et al., 1992).”
BackgroundDephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria
Cereghetti, G. M., Stangherlin, A., de Brito, O. M., Chang, C. R., Blackstone, C., Bernardi, P., & Scorrano, L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808249105 · Cited by 1,129 · cited 3×
“…Col6a1-/- mouse (Irwin et al., 2003), an issue of importance because calcineurin affects mitochondrial fission through dephosphorylation of Drp-1 (Cereghetti et al., 2008); (ii) that this drug is an effective inhibitor of the PTP in vivo, as demonstrated by its desensitizing effects in…”
BackgroundInfluentialSelf-citationJanssen, P. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00052-3 · Cited by 45 · cited 1×
“Remarkably, and at variance from the decreased contractile performance of human and rabbit heart muscle preparations caused by CsA (Janssen et al., 2000), Debio 025 was cardioprotective in a mouse model of myocardial infarction (Gomez et al., 2007) suggesting that the toxic effects of CsA are…”
Background
Cited by
Mitochondrial dysfunction in diabetic kidney disease
Forbes, J. M., & Thorburn, D. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.9 · Cited by 634
Roca, F. J., & Ramakrishnan, L. (2013) · Cell · doi:10.1016/j.cell.2013.03.022 · Cited by 592
“The first, alisporivir (Debio 025), is an orally administered drug that impedes CYPD's ability to regulate mPTPC and is currently in Phase III clinical development for Hepatitis C (Quarato et al., 2012; Tiepolo et al., 2009).”
BackgroundBernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 577
Self-citationMercuri, E., Bönnemann, C. G., & Muntoni, F. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32910-1 · Cited by 551
Molecular mechanisms and consequences of mitochondrial permeability transition
Bonora, M., Giorgi, C., & Pinton, P. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00433-y · Cited by 538
Metadata
- Authors
- Tiepolo, T., Angelin, A., Palma, E., Sabatelli, P., Merlini, L., Nicolosi, L., Finetti, F., Braghetta, P., Vuagniaux, G., Dumont, J., Baldari, C., Bonaldo, P., & Bernardi, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-07
- Volume
- 157
- Issue
- 6
- Pages
- 1045-1052
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2033518229
- Cited by
- 123
- References
- 3
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1−/−myopathic mice. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00316.x
- The paper
- Tiepolo, T., Angelin, A., Palma, E., Sabatelli, P., Merlini, L., Nicolosi, L., Finetti, F., Braghetta, P., Vuagniaux, G., Dumont, J., Baldari, C., Bonaldo, P., & Bernardi, P. (2009). The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1−/−myopathic mice. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00316.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.